Head & Neck Cancer

Immunotherapy may lead to a major change in how the treatment of metastatic recurrent head and neck cancer is approached, according to Barbara Burtness, M.D., a professor of medicine at Yale School of Medicine.

Despite associated toxicities, cisplatin chemotherapy induced superior efficacy compared with a new alternative among patients with HPV-positive oropharyngeal carcinoma.

The FDA has granted an accelerated approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

Patients who received chemotherapy, actively smoked and drank alcohol, and were diagnosed with head and neck cancer reported significantly higher rates of opiate use, according to study results presented at the American Society of Clinical Oncology (ASCO) 2018 Palliative and Supportive Care Symposium.

SCOTT WIESKAMP KNEW THE spot on his tonsil wasn’t normal.

In this week’s episode of CURE Talks Cancer, we spoke with Jill Kelly – wife of Pro Football Hall of Fame Quarterback Jim Kelly – about his bout with head and neck cancer, and how she copes as a caregiver.

Patients with head and neck cancer appeared to be receptive to lung cancer screening, according to recent research performed at the University of Iowa Hospitals and Clinics.

To combat the psychological effects from a lymphedema diagnosis, patients need to be equipped with the knowledge and understanding of what the condition is and how it is treated.

The Food and Drug Administration has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor.

Patients with cancer are 10 times less likely to have an opioid-associated death, according to recent research conducted at Duke University.

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

In this episode of CURE Talks Cancer, we spoke with Elizabeth Langdon, vice president of strategic communications and development at the Head and Neck Cancer Alliance, about how the organization helps to raise awareness for the prevention, early detection and research of head and neck cancer.

The mouth is also part of the body, and yet, it is only in the past few years that oncologists have begun recommending patients see a dentist before they begin treatment to be sure the teeth and gums are in good shape.

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.

In this special edition of CURE Talks Cancer, we spoke with NFL Hall of Fame quarterback Jim Kelly about his experience with head and neck cancer, and the humbling experience of winning the Jimmy V award for Perseverance at this year’s ESPY Awards.

In this week's episode, state senator Eli D. Bebout discusses his two bouts with cancer, and how his health struggles influenced his politics.

From genetic mutations to treatment behind bars, here's a roundup of our 2018 Summer issue.

In this week’s episode of CURE Talks Cancer, we spoke with Voigt about how he noticed a lump in a woman’s neck while watching tv and utilized the power of social media to find her – which ultimately led to a thyroid cancer diagnosis.